Core Insights - The early 2025 revenue for Zasturi is projected at $15.8 million, attributed to a foundational launch phase aimed at establishing reimbursement pathways and operational readiness [1] - The activation of the permanent J code on January 1, 2026, is expected to be a key catalyst for increasing adoption rates among prescribers [1] - Early 2026 performance metrics for Zasturi indicate that patient enrollment forms and new starts have exceeded the historical performance of the company's first product, Jelmyto [1] Strategic Positioning - Zasturi is positioned as the only FDA-approved primary office-based therapy, aiming to disrupt the standard of care by providing a non-surgical alternative to TURBT procedures [1] - The company estimates a peak revenue potential of over $1 billion for Zasturi, based on high physician adoption and significant market penetration in the underserved NMIBC segment [1] Market Performance - Jelmyto is projected to generate $94 million in revenue for 2025, reflecting steady demand in a mature market [1] - The company plans to leverage the expanded Zasturi sales force to provide additional support to the Jelmyto franchise [1]